Objective-To determine the incidence of haemorrhagic disease of the newborn in the British Isles, study risk factors, and examine the effect of vitamin K prophylaxis.
Introduction
It is almost 50 years since Dam and Doisy were jointly awarded the Nobel prize for medicine or physiology for the isolation of vitamin K1 from alfalfa and since the first trials showed that it protected against haemorrhagic disease of the newborn.' Although occasional cases of haemorrhagic disease of the newborn continue to be reported, most paediatricians will not see a single case in several years, allowing the impression that it is no longer a significant cause of morbidity and mortality. If that impression is false there are important implications for the use of vitamin K prophylaxis as there is no uniform practice in the British Isles.2' Using the system developed and organised by the British Paediatric Surveillance Unit,4 we have conducted a prospective survey of haemorrhagic disease of the newborn in the British Isles to determine its incidence, learn more about the condition, and investigate the efficacy of current methods of prophylaxis.
Subjects and methods
Cases of haemorrhagic disease of the newborn were enrolled in the study over two years from March 1988 to February 1990 by means of the report card system of the British Paediatric Surveillance Unit. For the study a case of haemorrhagic disease of the newborn was defined as: "Any infant under six months of age with spontaneous bruising/bleeding or intracranial haemorrhage associated with prolonged clotting times, not due to an inherited coagulopathy or disseminated intravascular coagulation." Paediatricians were asked to notify any proved or suspected case and subsequently to complete a questionnaire giving further details of each case, including data regarding pregnancy and delivery, use of vitamin K prophylaxis, method of feeding, mode and timing of presentation, underlying illness in the baby, laboratory findings, and outcome. Birth population data were obtained for Great Britain and Northern Ireland from the Office of Population Censuses and Surveys and for the Republic of Ireland from the Central Statistics Office, Dublin.
Results
In the 24 months during which haemorrhagic disease of the newborn was included among the conditions reportable to the British Paediatric Surveillance Unit 90% of all report cards were returned. In the first nine months there may have been underreporting because the condition was listed on the cards as "HDN," interpreted by some to mean haemolytic disease of the newborn; thereafter the full name "haemorrhagic disease of the newborn" was used on the cards.
Over the two years 78 cases were notified. A questionnaire for each case was sent to the reporting paediatricians, and the 70 returned allowed classification into one of four groups. These were (a) confirmed haemorrhagic disease of the newborn (appropriate history of haemorrhage, documented prolonged clotting times, normal or raised platelet count, no evidence of infection; n=25); (b) probable haemorrhagic disease of the newborn (appropriate history, diagnosis other than haemorrhagic disease of the newborn thought unlikely but lacking laboratory confirmation; n=2); (c) possible haemorrhagic disease of the newborn (incomplete data causes for bleeding other than haemorrhagic disease of the newborn thought likely; n= 13); and (d) "no case" (dubious history and incomplete data or confirmation of serious disease other than vitamin K deficiency which would predispose to bleeding-for example, thrombocytopenia (one case), disseminated intravascular coagulation (one case), extreme prematurity with complications (one case)-n= 15). Fifteen further cases were notified in error: 11 were cases of haemolytic disease of the newborn, two were cases in which the report card was incorrectly marked, and two were duplicates. This paper is concerned with the 27 confirmed and probable cases of haemorrhagic disease of the newborn. In 10 of the 27 cases the bleed which precipitated admission was an intracranial haemorrhage, although in seven of these there were preceding warning bleeds.
Vitamin K prophylaxis-Nineteen infants had not been given vitamin K prophylaxis, and six had received oral vitamin K (1 mg in five cases, 0 5 mg in one). In two cases there were no data about prophylaxis. One baby (case 20) was born in a unit where the policy was to give intramuscular prophylaxis to all babies and the case notes stated that it had been given. However, the father, who was present at delivery and subsequently, was sure that no injection had been given. The staff were unable to confirm the injection, and the reporting paediatrician concluded that vitamin K had not been given. This case is therefore included in the "no prophylaxis" group. The other baby (case 27) was born in a unit where oral prophylaxis was routine but there was no record that the baby had received it; this patient is presumed to would be breast fed,3 which allows calculation of a relative risk ratio of haemorrhagic disease of the newborn in breast fed infants of 12 0 (95% confidence interval 3-6 to 39 8) compared with bottle fed infants.
Other medication -In only one pregnancy (case 2) did the mother take any medication other than iron and vitamins-namely, phenytoin for epilepsy. The baby was not given prophylaxis, was solely breast fed, and presented on day 3 with bruising. Only one baby (case 25) received medication other than vitamins before presenting with haemorrhagic disease of the newborn. He had been given Dentinox drops (dimethicone) for colic for eight days.
Age at presentation -The figure illustrates the ages at presentation of the whole group and the subgroups of those presenting with intracranial haemorrhage, those with liver disease, and those with both conditions. 
Discussion
Twenty seven cases of haemorrhagic disease of the newborn were reported among 1 671 000 live births, a rate per 100 000 births of 1 62 (95% confidence interval 0-998 to 2-24). The data confirm that haemorrhagic disease of the newborn remains a cause of serious morbidity and mortality in the British Isles-in two years causing intracranial haemorrhage in 10 infants, two ofwhom died. The data also confirm that exclusive breast feeding is an important risk factor6-9 and that so called late haemorrhagic disease of the newborn (that is, presentation after the first week of life) is relatively common and frequently associated with intracranial haemorrhage.789a The increased incidence noted in the period April to September is consistent with the reported higher incidence during the warm season in Japan. and a greatly increased risk among those given no prophylaxis (81 -7; 11 to 610). In the absence of liver disease the increased risk associated with oral prophylaxis did not quite achieve significance (relative risk 5 8; 0-6 to 55), but as liver disease is rarely diagnosed at birth when prophylaxis is given and as in no case of haemorrhagic disease of the newborn was liver disease suspected before presentation with bleeding (see below) the distinction seems irrelevant in clinical practice.
As no confirmed case of haemorrhagic disease of the newborn was reported in a baby who had definitely received intramuscular vitamin K1 we conclude that this method of prophylaxis protects against the disease, even in babies with liver disease; reports to the contrary are exceedingly rare.8 In a recent survey of haemorrhagic disease of the newborn in Germany, where about 80% of units practise prophylaxis for all babies, three of the 14 reported cases were in babies who had received a single oral dose of vitamin K1, one in a baby who had received an intramuscular dose (1 mg), and the remainder in babies who had received no prophylaxis (R Von Kries, personal communication).
Haemorrhagic disease of the newborn was reported in only one baby born to a mother taking anticonvulsant medication, but we cannot conclude that the risk to such babies has been overemphasised in the past.0' A more likely explanation is that it is rare for these babies not to be given intramuscular vitamin K1, even in maternity units practising a selective policy for prophylaxis, though interestingly this was not reported as being a common indication for prophylaxis in such units.3
The figure and table II show that infants who developed haemorrhagic disease of the newborn after oral vitamin K prophylaxis presented later than those who were given no prophylaxis. It may be inferred that oral prophylaxis at birth protects against haemorrhagic disease of the newborn in the early weeks of life. In many this is enough to give complete protection because during this "protected" period they may be changed from breast feeding to formula milk supplemented with vitamin K. In others, however, after the early weeks the risk of haemorrhagic disease of the newborn may increase again if they remain breast fed and particularly if they have liver disease.
It is noteworthy that 14 babies, seven of whom later suffered an intracranial haemorrhage, had either warning bleeds before presenting with haemorrhagic disease of the newborn or a delay of at least one day before presentation and that in one probable case the haemorrhagic tendency resolved when the baby was changed from breast feeding to formula milk. Midwives, health visitors, and doctors must be aware that bleeding, even in an apparently well baby, requires urgent investigation. Bleeding from the gut, nose bleeds, spontaneous bruises, and persistent oozing from the umbilicus or after Guthrie testing must not be ignored as they may presage catastrophic haemorrhage. Babies other than those reported to this study may have had significant symptoms which were never brought to the attention of a paediatrician because they did not have a major bleed before their haemorrhagic tendency resolved spontaneously.
LIVER DISEASE It could be argued that babies with liver disease should have been excluded from the data because their haemorrhage was secondary to the underlying condition. However, we believe the essential point is that they, like the others, bled as a result of vitamin K deficiency, which is potentially preventable by prophylaxis. Hepatitis is clearly an important risk factor for such bleeding even after oral prophylaxis with vitamin K1 1 mg. In this series there were six cases of hepatitis, and in none was it suspected until after the presentation with bleeding. Hepatitis cannot be diagnosed clinically at birth, so these babies cannot be recognised as being at high risk of developing haemorrhagic disease of the newborn at the time when vitamin K is usually given; if a selective policy of prophylaxis is used they are likely to be selected for no prophylaxis.
It is extremely unlikely that there were no cases of neonatal hepatitis among the babies given intramuscular vitamin K1 (the substantial majority of newborns in the United Kingdom3), yet none developed haemorrhagic disease of the newborn in the study period and it is much more likely that they were protected. In some the hepatitis may have resolved spontaneously without ever causing concern or being diagnosed, while others would have presented with features of liver disease other than bleeding. Mild cholestasis has been identified in a number of infants presenting with late onset haemorrhagic disease of the newborn, but in our study there was only one other patient with a history of prolonged jaundice.
All The aims of this study were to document current patterns of prophylaxis policy in Great Britain and Northern Ireland, recording recent changes and determining the reasons for these changes.
Methods and results
In 1988 a questionnaire was sent to each special care baby unit in the United Kingdom (as listed by the Neonatal Nurses' Association) requesting information about policies of prophylaxis in each maternity unit they served, aimed at including all maternity unit deliveries. We asked which babies received prophylaxis, the route of administration, the dose, whether repeat doses were given, whether changes in policy had been made since 1982 and, if so, why. The total number of yearly deliveries in the catchment of each unit was established. Replies were received from 278 (87%) of identified units. Excluding tertiary referral units we received data from 255 units accounting for roughly 592 000 deliveries a year (three quarters of all deliveries).
All units gave vitamin K (phytomenadione) to all or selected babies either intramuscularly, orally, or, rarely, intravenously. Of 219 units that gave all babies vitamin K, in 152 this was by intramuscular injection. Sixty seven units gave oral vitamin K routinely, and in 64 of these, babies considered at high risk received vitamin K intramuscularly; in one unit babies considered to be at high risk received vitamin K intravenously. Thirty six units gave vitamin K only to selected babies considered to be at high risk (33 intramuscular, three oral vitamin K). One hundred and fifteen units gave supplementary doses to high risk babies.
Since 1982 there had been a shift towards a policy of prophylaxis for all babies and from intramuscular to oral administration as routine (figure). A total of 220 units gave 1 mg vitamin K orally or intramuscularly. Other doses for routine prophylaxis were: intramuscular 0 5 mg (17 units) and 0 25 mg (two); oral 0 5 mg (three), 0 25 mg (two), and 2-0 mg (one). Eighty one units reduced the dose for preterm and low birthweight babies.
Reports of haemorrhagic disease of the newborn were the main reason for changing to a policy of prophylaxis for all. Oral administration was increasingly used because of awareness that vitamin K is well absorbed by this route,3 concern about inadvertent use of intramuscular ergometrine-oxytocin, and general reluctance to give intramuscular injections. Changes in policy for vitamin K prophylaxis in special care baby units in United Kingdom Comment All special care baby units give vitamin K to at least some babies; 510000 (86%) babies a year were born in units where all received intramuscular or oral vitamin K.
A total of 78000 (13%) babies were born in units where most received no vitamin K and a small minority of high risk infants were selected to receive vitamin K. Very few units selected for prophylaxis babies who were breast fed or whose mothers took anticonvulsant or antituberculous drugs during pregnancy, although these are recognised risk factors for haemorrhagic disease of the newborn. Thus around 13% of breast fed babies born in the United Kingdom do not receive vitamin K. These babies are at risk of developing haemorrhagic disease of the newborn. 4 Since 1982 routine prophylaxis has become more widespread and the use oforal vitamin K has increased. Subcutaneous administration of vitamin K, which gives comparable blood concentrations to intramuscular administration, is not practised in the United Kingdom. The preparation for oral or subcutaneous administration (Konakion) is not licensed for administration by these routes in the United Kingdom.
